Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: A comparison of Ventana immunohistochemistry and fluorescence in situ hybridization

Cancer Cytopathology

Volumn 123, Issue 2, 2015, Pages 117-122

  Wang, Weiya ^a   Tang, Yuan ^a   Li, Jinnan ^a   Jiang, Lili ^a   Jiang, Yong ^a   Su, Xueying ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

anaplastic lymphoma kinase (ALK); cell block; fluorescence; fluorescence in situ hybridization (FISH); malignant pleural effusion; non small cell lung cancer; Ventana immunohistochemistry (IHC) assay

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PROTEIN TYROSINE KINASE;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; LUNG TUMOR; METABOLISM; PATHOLOGY; SMALL CELL LUNG CANCER;

HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; RECEPTOR PROTEIN-TYROSINE KINASES; SMALL CELL LUNG CARCINOMA;

EID: 84927171709     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21510     Document Type: Article

References (25)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ,. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer. 2002; 2: 37.
2. Herbst RS, Heymach JV, Lippman SM,. Lung cancer. N Engl J Med. 2008; 359: 1367-1380.
3. Kimura H, Fujiwara Y, Sone T, et al., EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer. 2006; 95: 1390-1395.
4. Han JY, Park K, Kim SW, et al., First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30: 1122-1128.
5. Maemondo M, Inoue A, Kobayashi K, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
6. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
7. Shaw AT, Kim DW, Nakagawa K, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385-2394.
8. Wu YC, Chang IC, Wang CL, et al., Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One. 2013; 8: e70839.
9. Teixido C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R,. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res. 2014; 3: 70-74.
10. Thunnissen E, Bubendorf L, Dietel M, et al., EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012; 461: 245-257.
11. Selinger CI, Rogers TM, Russell PA, et al., Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013; 26: 1545-1553.
12. Minca EC, Portier BP, Wang Z, et al., ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013; 15: 341-346.
13. Ying J, Guo L, Qiu T, et al., Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013; 24: 2589-2593.
14. Wynes MW, Sholl LM, Dietel M, et al., An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014; 9: 631-638.
15. Zhang X, Zhao Y, Wang M, Yap WS, Chang AY,. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer. 2008; 60: 175-182.
16. Kawahara A, Azuma K, Sumi A, et al., Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer. 2011; 74: 35-40.
17. Cai G, Wong R, Chhieng D, et al., Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer (Cancer Cytopathol). 2013; 121: 500-507.
18. Nakamoto M, Teramoto H, Matsumoto S, Igishi T, Shimizu E,. K-ras and rho A mutations in malignant pleural effusion. Int J Oncol. 2001; 19: 971-976.
19. Lee JH, Hong YS, Ryu JS, Chang JH,. p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion. Lung Cancer. 2004; 44: 33-42.
20. Liu X, Lu Y, Zhu G, et al., The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol. 2013; 66: 1065-1069.
21. Peled N, Palmer G, Hirsch FR, et al., Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012; 7: e14-e16.
22. Rodig SJ, Mino-Kenudson M, Dacic S, et al., Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15: 5216-5223.
23. Mino-Kenudson M, Chirieac LR, Law K, et al., A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010; 16: 1561-1571.
24. Paik JH, Choe G, Kim H, et al., Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011; 6: 466-472.
25. Wang WY, Liang DN, Yao WQ, et al., Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients. Hum Pathol. 2014; 45: 1414-1422.